(Veenendaal, 28 September 2010) Nucletron and MedCom GmbH & Pi-Medical Ltd, today signed a license agreement for the next generation seeds treatment planning module of Oncentra Prostate.
The new seeds planning tool, named Oncentra Seeds, is a breakthrough in seeds treatment planning systems. Nucletron’s total solution for prostate HDR and seeds treatment is offering unique features such as a fully integrated bi-plane transrectal ultrasound probe, prostate sector modelling, automatic needle reconstruction on live ultrasound images, ultrasound guided needle navigation and automated planning features. As a result of its intuitive, real-time and ergonomic structure, the best possible treatment can be accomplished in a very short timeframe. Oncentra Seeds works with Nucletron’s SeedSelectron, but also optimally with other seed delivery systems.
“We have been cooperating with MedCom & Pi- Medical since 1996. During that collaboration, we have continuously seen the innovation spirit of these two partners, demonstrated again in our new Oncentra Seeds product,” said John Lapré, VP Research and Development at Nucletron. “Oncentra Seeds completes our integrated prostate platform, combining state of the art technology with user friendliness in one unique product for seeds prostate treatment.”
Oncentra Seeds will be released in December as a new generation platform following Nucletron’s existing SPOT-Pro system for seeds treatment planning. The new product can be seamlessly integrated within Oncentra Prostate, a fully DICOM-compatible treatment planning system specialized for prostate cancer and offering a one-stop-solution from image acquisition over live planning to seeds delivery.“Our collaboration with Nucletron offers us a partnership with a strong, global leader in brachytherapy solutions. It is a natural partnership to work closely together on this next generation product to make it accessible to as many users as possible,” said G. Sakas of MedCom and Pi-Medical.
Nucletron provides state of the art radiotherapy solutions for cancer treatment that meet the evolving needs of patients, their caregivers and healthcare professionals around the world. Nucletron has unmatched global leadership in brachytherapy, a very precise, highly effective and well-tolerated treatment option for healthcare providers, tailored to the needs of individual patients. We work with clinical teams to constantly improve and develop an innovative portfolio of integrated products, software and services that assures excellent patient outcomes. Headquartered in Veenendaal, The Netherlands, Nucletron employs more than 500 employees, with offices in 15 countries, and products available in more than 100 countries around the world. Please visit http://www.nucletron.com/ to learn more about our healthcare solutions.
MedCom (http://www.medcom-online.de/) offers innovative and advanced imaging-based products with emphasis on cancer treatment, interventional & surgical navigation and specialized telemedicine solutions (trauma, military & Special Forces, rural areas, satellite). Based in Darmstadt, Germany, MedCom is providing OEM products to a large number of world-wide acting providers of integrated clinical solutions, but also high-end clinics from the research sector.
Pi-Medical (http://www.pi-medical.gr/) is a private high-technology company, founded in 2000 and located in Athens, Greece. Pi-Medical is focusing on research and development of new advance technology for cancer treatment and diagnosis. Concepts, algorithms and software tools developed by Pi-Medical are results of continuous research efforts and are available in several commercial systems distributed by our partners world-wide (OEM products).